Daewoong Pharmaceutical Indonesia

Daewoong Highlights Importance of LDL-C Management to Help Prevent Cardiovascular Complications in Patients with Diabetes

Writer

Manager

June 20, 2026

- Patient health talk show held with Siloam Hospitals Surabaya to raise awareness of early detection of cardiovascular and kidney diseases

- Patients with diabetes need comprehensive management of blood sugar, LDL-C levels, and kidney function

- Following the launch of dyslipidemia treatment Crezet, type 2 diabetes treatment Envlo is scheduled for launch in the first half of this year

‍

SURABAYA, Indonesia, June 20, 2026 — PT Daewoong Pharmaceutical Indonesia (“Daewoong”) held a patient health talk show in collaboration with Siloam Hospitals Surabaya to emphasize the importance of early screening and continuous treatment in preventing cardiovascular and kidney complications among patients with diabetes.

‍

The event was held under the theme “The Hidden Threat of Diabetes: Cardiovascular and Kidney Disease.” It was designed to help patients and their families understand that diabetes is not merely a matter of blood sugar control, but a serious condition that can lead to complications affecting major organs, including the heart, blood vessels, and kidneys.

‍

Diabetes is a major public health challenge in East Java. According to the Profil Kesehatan Provinsi Jawa Timur Tahun 2023 published by the East Java Health Office, the estimated number of patients with diabetes aged 15 and older in East Java reached 854,454 in 2023. Data from the Surabaya Health Office’s Profil Kesehatan Kota Surabaya 2023 also showed that 104,363 patients with diabetes were officially recorded in Surabaya.

‍

The first lecture was delivered by Prof. Yudi Her Oktaviono, Sp.JP(K), FIHA, a specialist in cardiology and vascular disease. He explained that heart attacks in patients with diabetes do not always come with warning symptoms such as chest pain. Prolonged high blood sugar can damage the nerves that transmit pain signals, meaning that even when a coronary artery becomes blocked, patients may not feel clear warning signs.

At the Health Talk organized by Daewoong Pharmaceutical Indonesia and Siloam Hospitals Surabaya in Surabaya on 20 June 2026, Prof. Yudi Her Oktaviono, Sp.JP(K), FIHA, a Cardiologist and Vascular Specialist, stated that LDL cholesterol originates from two sources, and blocking only one pathway is not sufficient.

‍

“Patients with diabetes may be exposed to cardiovascular risk without any obvious warning signs,” Prof. Yudi said. “This is why regular medical checkups and risk factor management should not be neglected, even when patients feel completely healthy.”

‍

He also explained that diabetes can accelerate the progression of atherosclerosis, a condition in which cholesterol and other substances build up inside the blood vessel walls, causing the vessels to narrow. LDL-C, commonly known as “bad cholesterol,” can enter damaged blood vessel walls and form arterial plaque. As plaque builds up, it can narrow or block the coronary arteries, increasing the risk of heart attack and stroke.

‍

As a core principle for cholesterol management, Prof. Yudi introduced “The Sooner, The Lower, The Better,” Daewoong’s cardiovascular disease prevention campaign message. He emphasized the importance of managing LDL-C early, lowering it sufficiently to the target levels recommended by healthcare professionals, and maintaining treatment consistently over the long term.

‍

The second lecture was led by Dr. dr. Soebagijo Adi Soelistijo, SpPD, Subsp. EMD(K), FINASIM, FACP, an internal medicine specialist and endocrinology consultant. He addressed the risks of diabetic kidney disease, explaining that it often has no specific symptoms in the early stages and is frequently detected only after kidney function has already declined significantly.

As a speaker in the second session of the Health Talk held at Siloam Hospitals Surabaya on 20 June 2026, Dr. dr. Soebagijo Adi Soelistijo, SpPD, Subsp. EMD(K), FINASIM, FACP, an Internal Medicine Specialist and Consultant Endocrinologist, discussed the risk of kidney disease caused by diabetes, which often shows no specific symptoms in its early stages and is frequently detected only after kidney function has significantly declined.

‍

“Continuous high blood sugar can gradually damage kidney tissue, much like a filter that wears down over time,” Dr. dr. Soebagijo said. “Because patients often do not notice abnormalities in the early stages, kidney screening should be done proactively rather than waiting for symptoms to appear.”

‍

He outlined three key tests that patients with diabetes should monitor regularly: HbA1c, UACR, and eGFR. HbA1c helps assess average blood sugar control, UACR detects small amounts of protein in the urine at an early stage, and eGFR evaluates the overall filtration function of the kidneys.

‍

Dr. Maria Magdalena Padmidewi, Sp.PK, Director of Siloam Hospitals Surabaya, said, “Diabetes education must go beyond simply lowering blood sugar levels. Patients and their families need to understand that diabetes can silently affect the heart, kidneys, blood vessels, and overall quality of life.”

At the Health Talk held at Siloam Hospitals Surabaya on 20 June 2026, as part of the collaboration between Daewoong Pharmaceutical Indonesia and Siloam Hospitals Surabaya, dr. Maria Magdalena Padmidewi, Sp.PK, Hospital Director of Siloam Hospitals Surabaya, emphasized that diabetes education should be delivered in a more comprehensive and holistic manner.

‍

“Siloam Hospitals Surabaya is committed to supporting early diagnosis, patient education, and integrated care to help prevent complications before they become severe,” she added.

‍

Baik In-hyun, Head of Daewoong Pharmaceutical Indonesia Business Division, said the educational initiative reflects Daewoong’s long-term commitment to supporting public health.

dr. Haritsah, Medical Affairs of Daewoong Pharmaceutical Indonesia, stated that the Health Talk themed “Silent but Deadly: Heart Attacks in People with Diabetes” reflects Daewoong’s long-term commitment to supporting public health and raising awareness of critical health issues.

‍

“When patients understand the connection between diabetes and its silently progressing complications at an early stage, they can begin preventive treatment before irreversible organ damage occurs,” Baek said. “Daewoong will go beyond ensuring a stable supply of innovative cardiovascular treatments and its independently developed type 2 diabetes treatment. We will continue to serve as a trusted partner in helping build healthier communities.”

From left to right: dr. Haritsah, Medical Affairs, Daewoong Pharmaceutical Indonesia; dr. Maria Magdalena Padmidewi, Sp.PK, Hospital Director of Siloam Hospitals Surabaya; Dr. dr. Soebagijo Adi Soelistijo, SpPD, Subsp. EMD(K), FINASIM, FACP, Internal Medicine Specialist and Consultant Endocrinologist; Prof. Yudi Her Oktaviono, Sp.JP(K), FIHA, Cardiologist and Vascular Specialist, served as speakers at the Health Talk organized by Daewoong Pharmaceutical Indonesia in collaboration with Siloam Hospitals Surabaya on 20 June 2026. The event aimed to raise awareness of the importance of early detection of cardiovascular and kidney diseases, encouraging patients to take proactive steps toward prevention and better health outcomes.

‍

Daewoong is expanding its treatment options to help patients with diabetes manage cardiovascular risks and blood sugar levels. Crezet, a dyslipidemia treatment launched in November last year, is a fixed-dose combination of ezetimibe and rosuvastatin, offering a new treatment option for patients who require strict LDL-C control.

‍

Envlo, Daewoong’s independently developed treatment for type 2 diabetes, obtained product approval from Indonesian authorities in December last year and is scheduled for launch in the first half of this year. Moving forward, Daewoong plans to strengthen collaboration with medical institutions to raise awareness of integrated management of blood sugar, LDL-C, and kidney function in patients with diabetes, while expanding access to advanced treatment options.

list

- Patient health talk show held with Siloam Hospitals Surabaya to raise awareness of early detection of cardiovascular and kidney diseases

- Patients with diabetes need comprehensive management of blood sugar, LDL-C levels, and kidney function

- Following the launch of dyslipidemia treatment Crezet, type 2 diabetes treatment Envlo is scheduled for launch in the first half of this year

Privacy Policy

이용약관